Newsletter
The Aducanumab Aftermath: The Payer

Tradeoffs

The Aducanumab Aftermath: The Payer

A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.This episode is part of a special weeklong series examining the potentially sweeping consequences this drug,…
June 24, 2021

The Aducanumab Aftermath: The Payer

A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.

This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.

Guest:

Mark Miller, PhD, Executive Vice President for Health Care, Arnold Ventures

Explore the full series and additional resources: https://tradeoffs.org/aducanumab

Read a transcript of this episode: https://tradeoffs.org/2021/06/24/the-aducanumab-aftermath-the-payer/

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter

Support this type of journalism today, with a gift: https://tradeoffs.org/donate

Follow us on Twitter: https://twitter.com/tradeoffspod


See acast.com/privacy for privacy and opt-out information.

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Join Our Newsletter

Proudly supported by:

cover
Treatment for Alzheimer’s Disease: Diet, Exercise and Lifestyle Changes Hear from people living with Alzheimer's about lifestyle changes they’ve adopted to continue leading active, social lives.